Superior Glycemic Control with Taspoglutide, a Once-Weekly Human GLP-1 Analog, Compared with Twice Daily Exenatide in Type 2 Diabetes (T2DM) Inadequately Controlled on Oral Agents: The T-emerge 2 Trial

被引：0
|
作者：
Rosenstock, Julio
Balas, Bogdan
Charbonnel, Bernard
Bolli, Geremia B.
Boldrin, Mark
Ratner, Robert
Balena, Raffaella
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A17 / A17
页数：1
相关论文
共 50 条
  • [41] Glycemic Control with Once-Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study
    Kazda, Christof M.
    Chien, Jenny
    Zhang, Qianyi
    Chigutsa, Emmanuel
    Landschulz, William
    Wullenweber, Paula
    Haupt, Axel
    Frias, Juan P.
    DIABETES, 2021, 70
  • [42] Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes (T2D)
    Grunberger, G
    Weston, WM
    Patwardhan, R
    Rappaport, EB
    DIABETES, 1999, 48 : A102 - A102
  • [43] DURATION-NEO-1: Greater A1C Reductions with Exenatide Suspension Once Weekly By Autoinjector Pen Vs Exenatide Twice Daily in Inadequately Controlled Type 2 Diabetes
    Wysham, Carol H.
    Rosenstock, Julio
    Malloy, Jaret
    Vetter, Marion
    He, Yaohua
    Ohman, Peter
    Iqbal, Nayyar
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [44] Taspoglutide added to metformin provides comparable glycaemic control as insulin glargine with superior weight loss and less hypoglycaemia in type 2 diabetes: The T-emerge 5 Trial
    Ampudia-Blasco, F. J.
    Nauck, M.
    Andjelkovic, M.
    Horton, E.
    Boldrin, M.
    Balena, R.
    DIABETOLOGIA, 2010, 53
  • [45] Albiglutide, a Weekly GLP-1 Agonist, Improved Glycemic Parameters in Japanese Type 2 Diabetes Mellitus (T2DM) Patients over 1 Year When Added to Single Oral Antihyperglycemic Medications
    Okuda, Inaha
    Wilson, Timothy H.
    Yue, Lin
    Nakajima, Hiro
    Carr, Molly C.
    Tsuboi, Maho
    Nino, Antonio
    DIABETES, 2016, 65 : A279 - A279
  • [46] Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
    Buse, John B.
    Sesti, Giorgio
    Schmidt, Wolfgang E.
    Montanya, Eduard
    Chang, Cheng-Tao
    Xu, Yizhen
    Blonde, Lawrence
    Rosenstock, Julio
    DIABETES CARE, 2010, 33 (06) : 1300 - 1303
  • [47] Once-weekly exenatide vs once- or twice-daily insulin detemir: randomised, open-label clinical trial of efficacy and safety in patients with Type 2 diabetes inadequately controlled with metformin alone or with sulphonylureas
    Davies, M.
    Heller, S.
    Sreenan, S.
    Sapin, H.
    Adetunji, O.
    Tahbaz, A.
    Vora, J.
    DIABETIC MEDICINE, 2013, 30 : 57 - 58
  • [48] Treatment of Type 2 Diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps?
    Sharma, Smriti
    Bhatia, Vinayak
    CHEMICAL BIOLOGY LETTERS, 2020, 7 (04): : 215 - 224
  • [49] Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
    Qiao, Qing
    Ouwens, Mario J. N. M.
    Grandy, Susan
    Johnsson, Kristina
    Kostev, Karel
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2016, 9 : 201 - 205
  • [50] DURATION-NEO-1: greater HbA1c reductions with exenatide suspension once weekly by autoinjector pen vs exenatide twice daily in inadequately controlled type 2 diabetes
    Wysham, C. H.
    Rosenstock, J.
    Malloy, J.
    Vetter, M.
    He, Y.
    Oehman, P.
    Iqbal, N.
    DIABETOLOGIA, 2014, 57 : S109 - S109
12345